Utah AI Chatbot Refills Prescriptions Without Doctor Approval

An AI chatbot in Utah has begun refilling prescriptions for residents without requiring traditional physician approval, marking what medical experts are calling an unprecedented shift in how healthcare services are regulated and delivered.

The program, launched quietly in January through a company called Doctronic, operates under Utah's "regulatory sandbox"—a framework that allows state officials to waive existing laws for AI companies testing promising technologies. Residents can visit a Doctronic website, answer questions about their medical history, and receive prescription renewals sent directly to their pharmacy if the AI determines no issues exist.

Why it matters

This pilot crosses a legal and ethical threshold that has defined American medicine for over a century: the requirement that only licensed medical professionals can prescribe medication. The program's structure—overseen by AI specialists rather than physicians, with federal regulators taking a hands-off approach—creates a regulatory gap that could set precedent for how AI medical services expand nationwide. The outcome will influence whether AI healthcare tools must meet the same rigorous standards as human doctors or operate under separate, potentially looser frameworks.

Medical boards excluded from oversight

Utah's medical licensing board learned about the program from news reports, according to Dr. Alan Smith, a family physician who chairs the board. In March, 11 board members sent a letter calling for the program to be halted, citing risks from automatically renewing medications that can cause side effects or dangerous drug interactions.

"We were essentially told: 'Yes this is going on. And no, you don't have a say in it,'" Smith said.

The refill program is currently overseen by a five-member board of AI specialists, none of whom are doctors. Human physicians review all Doctronic refill orders during this initial phase, but the company plans to transition to fully automated refills.

Regulatory uncertainty at state and federal levels

The program exists in a regulatory gray zone. Medical technology typically falls under federal Food and Drug Administration oversight, while medical professionals are licensed by states. Doctronic executives consider their AI part of state-regulated medical practice, but some experts believe the technology crosses into territory requiring FDA authorization.

When asked whether they sought FDA permission, Doctronic co-founder Dr. Adam Oskowitz declined to answer directly. "Our goal here is really just to meet patients where they need healthcare," he said. "We try not to get too deep into the weeds on the regulatory side."

An FDA spokesperson said the agency has not authorized any AI chatbots but "is committed to encouraging medical innovation" while keeping safety central.

Safety concerns and limited evidence

Dr. Eric Bressman of the University of Pennsylvania noted that "we have crossed a threshold in terms of giving something that is not human a medical license, whether or not we want to call it that."

Smith pointed to specific risks, including blood thinners on Doctronic's list of 190 refillable medications. These drugs can become dangerous if patients develop conditions like stomach ulcers that cause internal bleeding. "Just because something was prescribed before does not mean it's appropriate now," he said.

The only published study on Doctronic's technology—written by company scientists without independent review—showed the AI's diagnoses matched human doctors 80% of the time in 500 telehealth consultations. Utah has released some initial program data, and Doctronic plans to publish peer-reviewed studies later this year.

Expansion to other states

Texas and Wyoming have also created regulatory sandboxes for AI healthcare services. Lawmakers in Iowa, Idaho, and other states have introduced legislation to formally license AI medical services, many based on templates from the Cicero Institute, a pro-AI think tank founded by Palantir co-founder Joe Lonsdale.

Daniel Aaron of University of Utah's law school warned that companies expanding beyond available evidence "risk compromising public trust and fueling backlash" despite short-term business gains.

These details were first reported by the Associated Press.